Muta M - Search Results

1

Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.

Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Matsumoto G, et al. Among authors: muta m. Clin Cancer Res. 2005 Feb 1;11(3):1287-93. Clin Cancer Res. 2005. PMID: 15709200

2

Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.

Matsumoto G, Muta M, Umezawa K, Suzuki T, Misumi K, Tsuruta K, Okamoto A, Toi M. Matsumoto G, et al. Among authors: muta m. Int J Oncol. 2005 Nov;27(5):1247-55. Int J Oncol. 2005. PMID: 16211219

3

Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation.

Muta M, Matsumoto G, Nakashima E, Toi M. Muta M, et al. Clin Cancer Res. 2006 Jan 1;12(1):264-72. doi: 10.1158/1078-0432.CCR-05-1052. Clin Cancer Res. 2006. PMID: 16397051

4

Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Ueno T, et al. Among authors: muta m. Clin Cancer Res. 2000 Aug;6(8):3282-9. Clin Cancer Res. 2000. PMID: 10955814

5

Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.

Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Toi M, et al. Among authors: muta m. Int J Cancer. 2002 Mar 1;98(1):14-8. doi: 10.1002/ijc.10121. Int J Cancer. 2002. PMID: 11857378

6

Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread.

Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Bando H, et al. Among authors: muta m. Jpn J Cancer Res. 2002 Apr;93(4):389-96. doi: 10.1111/j.1349-7006.2002.tb01269.x. Jpn J Cancer Res. 2002. PMID: 11985788 Free PMC article.

7

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer.

Matsumoto G, Nagai S, Muta M, Tsuruta K, Okamoto A, Toi M. Matsumoto G, et al. Among authors: muta m. Oncol Rep. 2003 Sep-Oct;10(5):1201-6. Oncol Rep. 2003. PMID: 12883681

8

Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model.

Muta M, Matsumoto G, Hiruma K, Nakashima E, Toi M. Muta M, et al. Oncol Rep. 2003 Nov-Dec;10(6):1765-9. Oncol Rep. 2003. PMID: 14534693

9

DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice.

Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M. Matsumoto G, et al. Among authors: muta m. Oncol Rep. 2004 Aug;12(2):281-5. Oncol Rep. 2004. PMID: 15254689

10

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.

Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M. Suzuki E, et al. Among authors: muta m. Clin Cancer Res. 2007 Mar 15;13(6):1875-82. doi: 10.1158/1078-0432.CCR-06-1335. Clin Cancer Res. 2007. PMID: 17363544

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters